News

May 2025

Participation of Four non-PIC/S African National Regulatory Authorities in PIC/S Committee Meeting on 14-15 April 2025

Geneva, 26 May 2025:

During the PIC/S Committee Meeting held on 14-15 April at IATA Conference Centre in Geneva, we had the great pleasure of welcoming our Special Guests from four African National Regulatory Authorities (NRAs): the Nigeria National Agency for Food and Drug Administration and Control (NAFDAC – Nigeria), the Rwanda Food and Drugs Authority (RFDA – Rwanda), the Tanzania Medicines & Medical Devices Authority (TMDA – Tanzania), and the Senegalese Pharmaceutical Regulatory Agency (ARP – Senegal).

Their visit took place with support from a 3-year grant awarded to PIC/S by the Gates Foundation in May 2024 which aims at strengthening regulatory systems in Africa.

The PIC/S Committee Meeting was a valuable opportunity to meet the representatives of the four NRAs in person and exchange on our respective activities.

During a side-meeting, productive discussions were held about the NRAs’ motivations and the key requirements to initiate the PIC/S Pre-Accession Process. This conversation highlighted the NRAs’ strong commitment to strengthening GMP regulatory systems.

We look forward to a fruitful collaboration in the future!

July 2026

Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4)

Geneva, 30 July 2026

PIC/S has published the revised PIC/S Recommendations on Qualification and Validation (PI 006-4).

These Recommendations have been revised by a dedicated PIC/S Working Group, successively chaired by Norman Gray (UK / MHRA) and subsequently jointly chaired by Kevin O’Donnell (Ireland / HPRA) and Rebecca Dowd (USA / US FDA). They supersede the PIC/S Recommendations on Validation Master Plan; Installation and Operational Qualification; Non-Sterile Process Validation; and Cleaning Validation (PI 006-3).

PI 006-4 will enter into force on October 2026.

To download the revised Recommendations document, please consult the page “Publications”.

July 2026

2026 PIC/S Seminar (Istanbul / Türkiye)

Geneva, 28 July 2026: 

Registrations for the 2026 PIC/S Seminar on “Digital Transformation in GMP” which will be hosted by Türkiye / TMMDA from 4-6 November 2026 are now open (for Medicines Regulatory Authorities only). Deadline for registrations is 31 August 2026 (early-bird) and 23 October 2026 (standard).

For more information,  please contact the PIC/S Secretariat.

July 2026

United Arab Emirates applies for PIC/S Pre-Accession

Geneva, 28 July 2026:

On 15 July 2026, a Rapporteur was appointed by written procedure for the pre-accession application of Emirates Drug Establishment (EDE), for which a pre-accession application was received on 5 March 2026.

In line with the revised PIC/S Guidelines for the Pre-Accession Procedure, the designation of the Rapporteur marks the start of the pre-accession process.

July 2026

Uzbekistan applies for PIC/S membership

Geneva, 28 July 2026:

On 17 December 2025, the State Entity “Center of Good Practices” of the Pharmaceutical Industry Development Agency under the Ministry of Health of the Republic of Uzbekistan and the State Institution “Center for Pharmaceutical Products Safety” under the Ministry of Health of the Republic of Uzbekistan, submitted a joint membership application to PIC/S.

The application received was completed on 15 January 2026, further to which the Rapporteurs and Audit Team are in the process of being appointed by written procedure.

July 2026

Concept paper on the revision of EU-PIC/S GMP Annex 15 (Qualification and validation) - Corrigendum

Geneva, 16 July 2026:

The joint EMA - PIC/S drafting group has developed a concept paper on the revision of the Annex 15 (Qualification and validation) of the EU - PIC/S GMP Guide.

This concept paper aims to outline the rationale, objectives, and proposed changes for updating the Annex 15 - Qualification and validation, of the Good Manufacturing Practice (GMP) Guide, that is common to the Member States of the European Union (EU) / European Economic Area (EEA), as well as to the Participating Authorities (PAs) of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The aim of the revision is to extend the scope of the annex to active substances manufacturers and to consider the revision of ICH Guideline Q9 (R1) on quality risk management.

This concept paper was submitted to a joint EMA - PIC/S public consultation and comments have been collected until 9 April 2026. Following the public consultation, the initial timetable has been revised, and only this section has been updated accordingly.

The revised Concept Paper can be downloaded on the PIC/S website (link), as well as on the EMA website (link).